Crinetics Pharmaceuticals, Inc. 4

Crinetics Pharmaceuticals President & CEO Richard Scott Struthers exercised stock options into 19,928 shares of common stock on August 7, 2026, increasing his direct holdings to 424,706 shares.

On August 7, 2026, Richard Scott Struthers, President & CEO of Crinetics Pharmaceuticals, Inc., exercised four tranches of vested stock options for an aggregate 19,928 shares of common stock at exercise prices ranging from $15.29 to $25.19 per share, resulting in like-numbered increases in his directly held common stock and corresponding decreases in his option holdings. The transactions, all reported with transaction code "M" and marked as acquisitions in the common stock table, appear to be routine option exercises associated with previously granted equity awards that vest monthly over four-year schedules. Following these exercises, Struthers directly owned 424,706 shares of common stock, with substantial additional indirect holdings through multiple family trusts, a spouse account, and a charitable trust, while the exercised option awards now show zero remaining underlying shares. Using the reported exercise prices as a proxy for share value, the exercised shares represent an estimated aggregate value of roughly $389,000 and bring his directly held position to an estimated value of about $8.5–$9.0 million based on a blended price in the low‑ to mid‑$20s per share.

Filing Facts

CIK

1658247

Ticker

CRNX

Form

4

Source Type

fda

Accession

0001628280-26-055700

Alert Tier

5